Volume 31, Number 12—December 2025
Research Letter
Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA
Huanyu Wang
, Tori Embry, Kathy Everhart, Morgan Szekely, Jeanette Taveras, Sophonie J. Oyeniran, and Amy L. Leber
, Tori Embry, Kathy Everhart, Morgan Szekely, Jeanette Taveras, Sophonie J. Oyeniran, and Amy L. Leber
Table
Mycoplasma pneumoniae testing volume, number of positive tests, sequencing volume, resistance detection, and azithromycin prescriptions, by month, Ohio, USA, September 2023–May 2025*
| Month | Total cohort |
Urgent care center cohort |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. samples tested | No. (%) positive | No. (%) sequenced | No. (%) resistant | No. samples tested | No. (%) positive | No. (%) sequenced | No. (%) resistant | Azithromycin prescription rate† |
|||
| 2023 | |||||||||||
| Sep | 818 | 5 (0.6) | 0 | NA | 38 | 0 | 0 | NA | 4 | ||
| Oct | 1,001 | 29 (2.9) | 0 | NA | 55 | 6 (10.9) | 0 | NA | 6 | ||
| Nov | 1,348 | 59 (4.4) | 0 | NA | 102 | 7 (6.9) | 0 | NA | 8 | ||
| Dec |
1,697 |
62(3.7) |
0 |
NA |
160 |
13 (8.1) |
0 |
NA |
9 |
||
| 2024 | |||||||||||
| Jan | 1,388 | 57 (4.1) | 6 (10.5) | 0 | 79 | 13 (16.5) | 5 (38.5) | 0 | 6 | ||
| Feb | 1,303 | 29 (2.3) | 6 (20.7) | 0 | 76 | 4 (5.3) | 2 (50.0) | 0 | 5 | ||
| Mar | 1,085 | 45 (4.2) | 1 (2.2) | 0 | 62 | 12 (19.4) | 1 (8.3) | 0 | 5 | ||
| Apr | 965 | 56 (5.8) | 27 (48.2) | 0 | 73 | 14 (19.2) | 10 (71.4) | 0 | 6 | ||
| May | 1,045 | 106 (10.1) | 47 (44.3) | 0 | 130 | 36 (27.7) | 21 (58.3) | 0 | 8 | ||
| Jun | 1,020 | 266 (28.1) | 145 (54.1) | 1 (0.7) | 251 | 126 (50.2) | 82 (65.1) | 1 (1.2) | 25 | ||
| Jul | 1,318 | 407 (30.9) | 226 (55.5) | 2 (0.9) | 396 | 194 (48.7) | 124 (64.3) | 2 (1.6) | 35 | ||
| Aug | 2,009 | 642 (32.0) | 285 (44.4) | 10 (3.9) | 761 | 343 (45.1) | 180 (52.5) | 4 (2.2) | 51 | ||
| Sep | 3,067 | 860 (28.0) | 252 (29.3) | 11 (4.4) | 1,253 | 479 (38.2) | 133 (27.8) | 3 (3.0) | 69 | ||
| Oct | 5,657 | 1,831 (32.4) | 299 (16.3) | 26 (8.7) | 2,084 | 826 (39.6) | 108 (13.1) | 6 (5.6) | 109 | ||
| Nov | 6,943 | 1,649 (23.8) | 276 (16.7) | 13 (4.7) | 2,322 | 693 (29.8) | 117 (16.9) | 3 (2.6) | 131 | ||
| Dec |
6,210 |
1,288 (20.7) |
270 (21.0) |
17 (6.3) |
1,976 |
572 (29.0) |
120 (21.0) |
6 (5.0) |
109 |
||
| 2025 | |||||||||||
| Jan | 2,779 | 388 (14.0) | 121 (31.2) | 8 (6.6) | 587 | 146 (24.9) | 56 (38.4) | 2 (3.5) | 37 | ||
| Feb | 2,032 | 118 (5.8) | 27 (22.9) | 2 (7.4) | 300 | 36 (12.0) | 3 (8.3) | 1 (33.3) | 13 | ||
| Mar | 1,452 | 38 (2.6) | 14 (36.8) | 0 | 174 | 20 (11.5) | 9 (45.0) | 0 | 6 | ||
| Apr | 1,257 | 26 (2.1) | 8 (30.8) | 0 | 132 | 2 (1.5) | 2 (100) | 0 | 6 | ||
| May |
926 |
8 (0.9) |
4 (50.0) |
0 |
131 |
4 (3.1) |
2 (50.0) |
0 |
7 |
||
| Total | 45,320 | 7,969 (17.6) | 2,014 (25.3) | 90 (4.5) | 11,142 | 3,545 (31.8) | 975 (27.5) | 28 (2.9) | |||
*NA, not available. †Per 1,000 patients.
Page created: December 11, 2025
Page updated: January 01, 2026
Page reviewed: January 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.